Stefan Luzi - Gilde Healthcare

team
Venture&Growth

All team members
Stefan Luzi
Partner Therapeutics
Venture&Growth
The Netherlands

Stefan Luzi

Partner - Therapeutics
Venture&Growth

Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on venture and growth capital investments in the biopharmaceutical sector. He led several investments and currently represents Gilde on the boards of Lava Therapeutics B.V. and Amphista Therapeutics Ltd.

Prior to joining Gilde, Stefan worked at Merck KGaA where he completed international assignments in the Global Business Intelligence and M Ventures divisions. Additionally, he was involved in various consulting projects spanning the pharmaceutical and chemical departments at Merck and co-moderated Merck Serono’s innovation competitions.

Stefan received a B.Sc. in Biology and M.Sc. in Biotechnology from the Swiss Federal Institute of Technology Zurich (ETH) and his MPhil in Bioscience Enterprise from the University of Cambridge. He completed his Ph.D. with Nobel Laureate Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge, where he developed a bicyclic peptide-based drug discovery platform.

He is a Swiss citizen based in Gilde’s Utrecht office.

Mika Nishimura

Operational Partner
Mika is a commercialization executive with extensive leadership experience in conceiving, planning, and launching disruptive medical technologies in 50 markets across North America, EMEA, Asia-Pacific, and Latin America.  She has an exceptional track record of...

Geoff Pardo

General Partner Healthtech
Venture&Growth
Geoff Pardo joined Gilde Healthcare in 2011 as a Partner working out of the office in Boston/Cambridge, MA and is focusing on Gilde's investments in North America. He led the investments in Ablative Solutions, Inari...

Joep Muijrers

General Partner Public Investments
Venture&Growth
Joep Muijrers joined Gilde in 2021 with two decades of broad experience in life sciences, including senior roles in portfolio management, company operations and investment banking. Most recently, he served as Chief Financial Officer and...